NERVIGESIC 150 CAP is a high-strength nerve pain relief medication formulated with Pregabalin 150 mg, a widely accepted therapeutic agent in the management of neuropathic pain and central sensitization syndromes. This product is particularly effective for individuals suffering from chronic nerve pain due to diabetic neuropathy, spinal cord injury, post-herpetic neuralgia, and fibromyalgia. It is also indicated as an adjunct in partial seizure management and for generalized anxiety disorders, enhancing both neurological and psychological well-being.

The active ingredient, Pregabalin, acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding reduces the influx of calcium into neurons, thereby dampening the excessive release of neurotransmitters such as glutamate, noradrenaline, and substance P. By controlling these neurochemical pathways, NERVIGESIC 150 CAP reduces the intensity of nerve pain, alleviates mood disturbances, and improves sleep patterns.

This 150 mg strength is typically prescribed when lower doses of Pregabalin are insufficient for symptom control. It delivers stronger pain relief, making it ideal for moderate to severe cases of nerve-related discomfort. The product is particularly beneficial in cases where patients experience symptoms like burning, tingling, electric shock sensations, or hyperalgesia, all hallmarks of neuropathic disorders.

NERVIGESIC 150 CAP is manufactured by Bluepill Express using advanced pharmaceutical technology under WHO-GMP and ISO-certified conditions. The capsule form is designed for enhanced bioavailability, consistent drug release, and patient compliance. It comes in tamper-resistant, moisture-protective packaging to maintain its stability and potency throughout its shelf life.

Patients using NERVIGESIC 150 CAP often report improvements not only in pain intensity but also in quality of life, sleep quality, and anxiety reduction. The medication is typically administered once or twice daily, depending on the patient’s clinical need and tolerance. It may be introduced gradually in dose titration protocols to minimize side effects such as dizziness or drowsiness, which are usually self-limiting and manageable.

As part of chronic pain treatment regimens, NERVIGESIC 150 CAP plays a central role in restoring mobility, independence, and emotional balance. It offers a comprehensive approach to both physical and mental symptoms of chronic pain syndromes. Because of its neuro-modulating properties, it also finds wide application in pain clinics, neurology practices, and psychiatric settings where chronic anxiety and sleep disruption coexist with pain.